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RUSCH and his colleagues (Rusch, Bosch, and Boutwell, 1955; Boutwell,
Rusch, and Bosch, 1955; Boutwell, Rusch, and Booth, 1956) have reported the
appearance ofboth benign andmalignanttumours ofthe skin ofmice after repeated
applications of phenol, of a number of substituted phenols, of iodoacetic acid, and
of croton oil. Some of these mice had received a previous single "initiating"
dose (75 /ug.) of 9: 10-dimethyl-1: 2-benzanthracene (DMBA), others had not.
They state that in the case of croton oil, pretreatment with the carcinogen was
necessary for tumour production in one stock strain of mice, but not in another
(Rusch et al., 1955).t
It was found in this laboratory (Roe, 1956) that prolonged treatment of the
skin of mice of the " S " strain with croton oil resulted in the appearance of a
small number of benign tumours after a long latent period, and of occasional
malignant tumours after a still longer period. The incidence of both types of
tumour was much lower, and the latent period much longer, than in the case of
the tumours recorded by Rusch and his colleagues, for their mice, treated similarly.
Moreover, it wasfoundhere that aprevioussingle application ofDMBAenormously
accelerated the appearance and increased the incidence or papillomata which
followed croton oil treatment of the " S " strain, though at least half of them
regressed afterthe cessationoftreatment. Pretreatmentwith DMBA alsoincreased
the incidence of malignant skin tumours in the " S " strain (Roe, 1956a, b,
Salaman and Roe, 1956).
To what may this discrepancy be attributed ? DMBA was applied in this
laboratory as 0.2 ml. of a 0- 15 per cent solution in acetone and allowed to spread
all over the back. Rusch and his colleagues applied 1 drop (approximately 0.025
ml.) of a 0 3 per cent solution of DMBA in acetone or benzene. This volume
spreads over an area about 12 mm. in diameter. Croton oil is applied here as
0 3 ml. ofa 0 1 to 0.5per cent solution in acetone to the whole back. TheAmerican
workers used 1 drop ofa0.5per centsolution inbenzene or acetone. Inthe authors'
opinion it is unlikely that these differences in technique account for the different
effects observed. It is much more likely that a difference in susceptibility of the
strains of mice used to skin carcinogenesis is responsible. Very great differences
in susceptibility to this type of carcinogenic treatment do in fact exist between
different strains of mice (Rusch, Bosch, and Boutwell, 1955; Salaman, 1956).
* Now of the Bacteriological Department, London Hospital Medical College, London, E.1.
t Since this work was completed the suggestion has been made (Shubik, 1957), that the high
incidence of tumours observed by Rusch and his colleagues in a strain of dealer's mice treated with
croton oil alone may have been due to initiation by a preservative used on wooden breeding boxes by
the dealer from whom they were obtained. Boutwell, Bosch, and Rusch (1957) have investigated
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If this is the explanation, a similar discrepancy in the results of application of
the phenols may be expected.
The action of phenol on mouse skin, with and without previous treatment
with DMBA, has been re-investigated, using " S " mice, a stock albino strain
used in this laboratory for other studies on skin tumour initiation and promotion
(e.g. Salaman and Gwynn, 1951; Salaman and Roe, 1956). Several other agents
which have a sclerosing action similar to that of phenol have also been tested as
promoting agents.
MATERIALS AND METHODS
Mice.-Stock albinos of the " S " strain (Salaman and Gwynn, 1951) were
used. They were fed on cubes prepared according to the Rowett Institute formula
(Thomson, 1936) plus fresh greenstuff twice a week, and water ad libitum. All
were inoculated on the tails with vaccinial sheep lymph, as a precaution against
ectromelia (Salaman and Tomlinson, 1957). The hair was clipped from the back
before treatment, and at intervals again when necessary.
Chemical ayents.-9: 10-Dimethyl-1: 2-benzanthracene (DMBA) was obtained
from Messrs. L. Light & Co; Phenol (analar standard) from Hopkin & Williams
Ltd.; Ethanolamine oleate B.P. from British Drug Houses Ltd.; Proflavine
hemisulphate B.P. from May & Baker Ltd. Acetone (analar grade of British
Drug Houses) was used as solvent for the DMBA, and sterile distilled water for
the substances injected intradermally. Two parts of Carbowax 300 (obtained
from Gemec Chemicals Co.) to 1 part of distilled water was used as solvent for
proflavine hemisulphate applied to the skin. Solid pellets for subcutaneous
implantation were made by suspending proflavine hemisulphate powder in melted
paraffin wax (m.p. 55° C.), and extruding while warm to form rods approximately
1.5 mm. diameter.
Experiment I
Rusch and his colleagues applied single drops (approx. 0 025 ml.) of 5, 10, and
20 per cent phenol to the backs of mice, twice weekly. They mention that the
highest concentration produced extensive ulceration, and some deaths due to
phenol intoxication.
In preliminary tests on the " S " strain it was found that 0 025 ml. of 20 per
cent phenol in acetone (5 mg. anhydrous phenol) applied to the skin of the back
caused transitory toxic symptoms manifested by shivering, and local ulceration
of the skin which took about 3 weeks to heal. It was judged inadvisable to apply
this dose to the same site as frequently as had been done by the American
workers.
The application of the same dose of phenol (5 mg. anhydrous) as 0.1 ml. of a
5 per cent solution in acetone produced the same transitory toxic symptoms,
but no ulceration. This application spread over about half the back, and was
followed by light crusting only.
As a result ofthese tests it was decided to apply a dose of 5 mg. phenol weekly
in two ways: (1) 0.025 ml. 20 per cent phenol in acetone to one of four sites, left
scapular region, right haunch, right scapular region, and left haunch, in that
order successively, and (2) 0-1 ml. 5 per cent phenol in acetone to the anterior
and posterior halves ofthe back successively.
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Eighty male mice ofthe" S "strainwere dividedinto 4groups of20, andtreated
as follows:
Group 1.-02 ml. 0.15 per cent DMBA in acetone was applied to the
whole back. After an interval of 3 weeks, weekly applications of 0 025 ml.
20 per cent phenol in acetone were begun. Four sites of application (left
scapular region, right haunch, right scapular region, left haunch) were used
in rotation, one only being treated each week. This treatment continued
for 24 weeks, when each site had received 6 applications at 4-weekly
intervals.
Group 2.-No pretreatment with DMBA was given. Twenty per cent
phenol was applied weekly to the back, as to Group 1, for 32 weeks.
Group 3.-Pretreatment with DMBA was given as to Group 1. After
3 weeks 0.1 ml. 5 per cent phenol in acetone was applied alternately to the
anterior and posterior halves ofthe back every week for 32 weeks.
Group 4.-No pretreatment with DMBA was given. Five per cent
phenol was applied weekly to the back, as to Group 3, for 32 weeks.
Throughout treatment the 20 per cent phenol solution continued to produce
local ulceration, which healed just in time for the next application to the same
site 4 weeks later, while the 5 per cent phenol solution continued to produce only
light transient crusting, which tended to decrease as the experiment progressed.
Mice ofGroup 1 were killed at the 39th week, because of poor condition and the
presence oflarge tumours. Mice of the other groups were killed at the 45th week.
Tumours began to appear on or near the treated sites in Group 1 after 8 appli-
cations of20per centphenol (i.e. two to each ofthe foursites) andrapidly increased
in number andsize. At the 37th week (10 weeks after theendofphenoltreatment)
there were 11 tumour-bearing mice out of 13 survivors, with a total of 74 tumours.
Five histologically confirmed malignant tumours arose in this group, 3 of which
were squamous epitheliomas, and two were of spindle-cell type. One of the latter
metastasized to the regional lymph glands and to the lungs.
Tumours began to appear in Group 3 after 13 weekly applications of 5 per cent
phenol (7 to the anterior and 6 to the posterior halves of the backs). At the 37th
week (3 weeks afterthe end ofphenoltreatment) there were 4tumour-bearing mice
out of 14 survivors, with a total of 9 tumours. Two histologically confirmed
malignant tumours arose in this group: a squamous epithelioma, and a malignant
myxosarcoma which was removed but recurred locally and on the opposite
flank, and metastasized to the spleen.
In Group 2 seven papillomas arose. The first appeared after 24 weekly appli-
cations of 20 per cent phenol (6 to each site). No malignant tumours appeared.
One mouse bore a small subcutaneous haemangioma, of a type commonly seen
after a variety of treatments.
In Group 4 no tumours appeared.
No tumours arose remote from the treated areas in any of these groups (cf.
Groups 5, 6, and 7). The course of tumour development in Groups 1, 2, and 3,
is illustrated in Fig. 1.
These results give qualitative confirmation to those of Rusch et al. (1955).
Twenty per cent phenol, applied less frequently than in their experiments, to
mice which probably have a lower susceptibility to skin carcinogenesis than theirs,
acted powerfully as a tumour promoting agent when used after a single application
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of DMBA. It also produced a small number of tumours when used alone. But the
quantitative difference between these two effects was greater in our experiments
than in theirs.
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FIG. 1.-Tumour promotion by phenol applied to the skin. Twenty mice in each group.
o Group 1: DMBA applied once to skin, followed by weekly applications of 20 per cent
phenol.
* Group 2: DMBA applied once to skin, followed by weekly applications of 5 per cent
phenol.
A Group 3: Weekly applications of 20 per cent phenol only.
Figures in brackets represent numbers of survivors.
The carcinogenic effect of weekly applications of the highly ulcerative 20 per
cent phenolwhen usedalone was infact weakerthanthatofthe muchlessdamaging
0 17 per cent croton oil used alone, recorded in a recent report from this laboratory
(Roe, 1956b). The promoting effects of these two agents used after initiation with
DMBA was quantitatively similar with respect to papilloma production, but
phenol promoted a higher proportion of malignant tumours than croton oil.
The weaker (5 per cent) phenol solution had significant promoting, but no demon-
strable carcinogenic, action. We conclude that phenol, like croton oil, is a potent
I
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promoter of tumour development, but a weak carcinogen, under the conditions of
the present experiment.
The higher concentration of phenol, as previously noted, produced frank
ulceration followed by scarring, while the lower concentration produced slight
and transient crusting only. Microscopic examination of skin treated with these
solutions showed that 20per cent phenol produces necrosis of all layers ofthe skin,
with gross epidermal hyperplasia and dermal thickening for some distance around
the ulcer; 5per cent phenolproduces destruction ofthe epidermis andhairfollicles,
which is repaired before the 8th day, leaving a moderately thickened epidermis
and only slight dermal changes (Fig. 2 and 3).
That severe injury involving all layers of the skin, and the resultant scarring
is tumour-promoting, but that superficial injury involving the epidermis only is
ineffective in this respect, has been suggested by Linell (1947). In considering the
superiority of 20 per cent over 5 per cent phenol in tumour-promoting power it
is necessary to take account of the possible role of ulceration. The local damage
produced by 0.015 ml. of 20 per cent phenol is certainly severe, and the resultant
scarring extensive. The application of 0.1 ml. 5 per cent phenol produces a degree
of damage and resulting superficial crusting, with slight thickening of the fibrous
layer of the dermis, which is often seen in mice treated with 0.1 to 0 3 per cent
acetone solutions of croton oil. Such a slight degree of damage, it seems fairly
certain (Linell, 1947), is not itself tumour-promoting.
In the hope of getting experimental evidence which would help to settle this
question, a number of substances known to produce sclerosis were injected intra-
dermally into mice which had received one external application of DMBA to the
skin. These substances, and their concentrations, were chosen with the object
of producing the maximum dermal sclerosis with the minimum of damage to the
EXPLANATION OF PLATES
FIG. 2.-The edge of an ulcer 8 days after the application of0-025 ml. 20 per cent phenol to the
back of a mouse (as to Groups 1 and 2).
FIG. 3.-An area of skin 8 days after the application of 0 1 ml. 5 per cent phenol (as to Groups
3 and 4).
FIG. 4.-Six mice of Group 1. (One application of DMBA followed by weekly applications of
20 per cent phenol.) Several tumours are visible.
FIG. 5.-Eight mice of Group 2. (No DMBA. Weekly applications of 20 per cent phenol.)
The scars of ulcers, but no tumours, are visible.
FIe. 6.-A malignant tumour from the left haunch of a mouse in Group 3, showing squamous
epithelioma cells infiltrating between the muscle bundles of the panniculus carnosus.
FIG. 7.-The edge of an ulcer 9 days after one intradermal injection of 0'1 per cent proflavine
hemisulphate (as to Groups 5 and 8).
FIG. 8.-A mouse ofGroup 5. 42nd week. (One application ofDMBA followedbyweeklyintra-
dermal injections of0'1 per cent proflavine hemisulphate.) A malignant tumour is visible on
the left haunch. The right inguinal gland is enlarged, and was found to contain a metastasis
(see Fig. 9 and 10).
FIG. 9.-A malignant tumour from the left haunch of the mouse shown in Fig. 8, containing
groups of squamous cells separated by bundles of spindle cells.
FIG. 10.-A secondary deposit of squamous carcinoma in the right inguinal gland of the same
mouse.
FIG. 11.-A basal cell tumour from the right scapular region of a mouse in Group 6.
Notes.-Sections. Fixed in Zenker's fluid, stained with Eosin-Biebrich Scarlet (Salaman and
Gwynn; 1951).
Magnification: Fig. 2, 3, 7 X 33.
Fig. 6, 9, 10, 11 x 180.
For the later history of mice shown in Fig. 4 and 5, see p. 436.
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epidermis. The injections were made through a long fine needle (50 mm. long
and 0.6 mm. diameter) with a short bevel, which was introduced into the sub-
cutaneous space just in front of the root of the tail, and directed to one of the
quadrants ofthe back. The point was then pressed upwards so that it entered the
dermis. When the point was correctly placed the subsequent injection caused a
persistent bleb.
Experiment II
Three substances were chosen:
Phenol.-It was clearly advisable to include phenol, not only because it had
been used in the previous experiment, but also because it is used clinically as a
sclerosing agent. It was found after trial that 0.1 ml. of a 0 5 per cent aqueous
solution of phenol injected intradermally into mouse skin produced a firm and
persistent dermalthickening, and in some cases a small ulcer, which healed in about
10 days.
Ethanolamine oleate.-Tbe B.P. formula which is used for the injection of
varicose veins contains ethanolamine 0.91 g., oleic acid 4.23 g., and benzyl alcohol
2.0 ml., per 100 ml. water. The preparation used also contained 0.1 per cent
chlorcresol. Intradermal injection of 0.1 ml. of a 33 per cent solution of this
preparation in water was followed by the appearance of a lesion similar to that
produced by 0-5 per cent phenol, but with rather more ulceration, which took a
little longer to heal.
Proflavine.-This substance was used by McIntosh and his colleagues (1943)
in order to produce a sclerotic nodule in the subcutaneous tissue of fowls. Rous
sarcoma virus injected elsewhere was found to localize and induce tumours at the
sites ofinjection of the profiavine. 5-Aminoacridine was also effective when used
in this way. 0.1 ml. of 0.1 per cent proflavine hemisulphate in water injected
intradermally into mouse skin was found to produce a lesion of about the same
severity as 0 5 per cent phenol.
Histological examination of the lesions produced by intradermal injections of
these substances showed that all three produced a rapid degenerative change,
sometimes amounting to necrosis, of a small patch of dermis and epidermis. This
was followed by inflammatory changes in the dermis and subcutaneous tissue,
and marked epidermal hyperplasia at the margins of the lesion, with overgrowth
and distortion ofhair follicles. At 10 days some epidermal hyperplasia and dermal
fibrosis was seen, but in almost all cases the epidermis was continuous over the
lesions. These changes are illustrated in Fig. 7.
All 3 substances were injected intradermally, with and without previous appli-
cations of DMBA, following a schedule similar to that used for the applications
of 20 per cent phenol (see Groups 1 and 2 above).
Six groups (5-10), each of 20 male mice of the " S " strain were treated as
follows :-
Group 5.-02 ml. 0-15 per cent IDMBA in acetone was applied to the
skin of the back (as to Groups 1 and 3). After an interval of 3 weeks
0.1 ml. 0-1 per cent proflavine hemisulphate in distilled water was injected
intradermally into four areas, left scapular region, right haunch, right
scapular region, and left haunch, in rotation (according to the schedule
described for Group 1), weekly for 24 weeks.
30
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Group 6.-DMBA was applied as to Group 5. After an interval of 3
weeks 0.1 ml. 33percentethanolamine oleate B.P. indistilledwater (equiva-
lent to 1 6 per cent ethanolamine oleate) was injected intradermally,
according to the same schedule, weekly for 24 weeks.
Group 7.-DMBA was applied as to Group 5. After an interval of 3
weeks 0.1 ml. of a solution of phenol in distilled water was injected intra-
dermally weekly according to the same schedule, 0.5 per cent for 12 weeks,
and 1 per cent for a further 12 weeks. (The increase in concentration was
made because the lower concentration had ceased to produce a visible
effect on the skin.)
Groups 8, 9, and 10.-No DMBA was applied. The same intradermal
injections, for the same periods, as in Groups 5, 6, and 7, respectively, were
given.
In Group 5 (DMBAfollowed byproflavinehemisulphate) atumour arose during
the 6th week ofthe experiment, on a site which had received only one injection of
proflavine. Others appeared soon afterwards. At the 33rd week there were 12
tumour-bearing mice out of 17 survivors, with a total of 28 tumours at or near the
injection sites.
In Group 6 (DMBAfollowed byethanolamine oleate) a tumour appeared during
the 11th week on a site which had received two injections ofethanolamine oleate;
this later regressed. A few others appeared from the 15th week onwards, and at
the 33rd week there were 6 tumour-bearing mice out of 18 survivors, with a
total of 8 tumours at or near the injection sites.
In Group 7 (DMBA followed by phenol) 5 tumours appeared on 2 out of 20
mice at the 23rd week, at the time of the 22nd phenol injection. This incidence
did not increase.
The course oftumourdevelopment in Groups 5, 6, and 7, is illustrated inFig. 12.
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FIG. 12.-Tumour promotion by intradermal injections of proflavine hemisulphate, ethanol-
amine oleate and phenol. Twenty mice in each group.
O Group 5: DMBA applied once to skin, followed by weekly intradermal injections of
profiavine hemisulphate.
* Group 6: DMBA applied once to skin, followed by weekly intradermal injections of
ethanolamine oleate.
A Group 7: DMBA applied once to skin, followed by weekly intradermal injections of
phenol.
Figures in brackets represent numbers of survivors.
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In the control Groups 8, 9, and 10, injected with profiavine hemisulphate,
ethanolamine oleate, and phenol, respectively, without previous treatment with
DMBA, 2 tumours were seen at or near the injection sites: one in the profiavine
group which appeared 5 weeks after the last injection and disappeared 7 weeks
later, and one in the ethanolamine oleate group which appeared one week after the
last injection and persisted.
In addition to these tumours a number ofothers appeared on the heads, necks,
and limbs of mice of Groups 5, 6, and 7, i.e. remote from the sites of intradermal
injection. Their significance will be discussed below.
Benign and malignant tumours have been counted together in the above
record. Most were benign, and remained so, but five squamous epitheliomata
developed at injection sites in 4 mice of Group 5; the first appeared at the 23rd
week, and the others between the 30th and 50th week. A squamous epithelioma
arose at an injection site in Group 6 at the 30th week, and 2 arose in Group 7,
one on the neck at the 45th week and one on a treated site at the 50th week. The
latter metastasized to a lymph gland and to the lungs. In addition 2 mice in
Group 6 developed multifocal basal cell tumours, on the neck in one, and on an
injection site and on the head in the other; these tumours appeared between the
42nd and 46th week. (This type of tumour is occasionally induced in mice of
this strain by other carcinogenic applications. They appear most commonly on
the head or neck.)
Experiment III
A number of further tests were made with the object of discovering whether
profiavine applied repeatedly to the skin in a suitable solvent, or implanted
subcutaneously in a vehicle which would ensure its persistence at the site for a
long time, would have tumour-promoting power. After some trials the following
methods were used. Four groups, each of20 3 mice ofthe" S "strain, were used.
Group 11.-02 ml. 0.15 per cent DMBA in acetone was applied to the
skin of the back (as to Groups 1, 3, 5, 6, and 7). After an interval of 3
weeks, weekly applications to the same area of 0 3 ml. of a 1 per cent
solution of profiavine hemisulphate in water one part, carbowax 300 two
parts, were begun and continued for 24 weeks.
Group 12.-No pretreatment with DMBA was given. Profiavine
hemisulphate was applied to the back as to Group 11.
Group 13.-Pretreatment with DMBA was given as to Group 11. After
3 weeks two cylindrical pellets, approximately 16 mm. long and 1.5 mm.
in diameter, consisting of 2 5 mg. crystalline profiavine hemisulphate
suspended in paraffin wax, were implanted subcutaneously in the back so
that they lay parallel, and about 1 cm. lateral, to the spinal column.
Group 14.-No pretreatment with DMBA was given. Profiavine
hemisulphate pellets were implanted as in Group 13.
Groups 11 and 12 were observed for 31 weeks, and Groups 13 and 14 for 47
weeks. No tumours arose on the treated sites in any of these groups. A few
tumours arose on the heads in Groups 11 and 13 (cf. Groups 5, 6, and 7).
No ulceration or other naked-eye abnormality was produced in Groups 11 and
12 (profiavine to skin). Microscopical examination showed no abnormality 3
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days after the first profiavine treatment; when the animals were killed small
areas of slight epidermal thickening were found on several, in others no abnorma-
lity was seen.
In several mice in Groups 13 and 14 (subcutaneous profiavine pellets) the skin
ulcerated over the pellet, which was discharged. The resulting ulcers were indolent,
and sometimes enlargedintofairlyextensive scabbed areas. Some ofthesepersisted
until the animals were killed two to three months later. When they were killed
(50 weeks after the application of DMBA to Group 13, and 47 weeks after the
implantation of the pellets) about half the pellets were still in situ. The pellets
themselves were a dark yellow colour, but the surrounding tissue was hardly
coloured. In some cases firm fibrous nodules were found either surrounding
or in close association with the pellets, and subcutaneous purulent abscesses
had formed under some of the ulcers.
Microscopically the pellets were found to be surrounded by thin fibrous
capsules. Several ofthese capsules had been partly lined by keratinized squamous
epithelium, and were surrounded by considerable fibrous dermal thickening. There
was slight epidermal hyperplasia over these sites, and in their vicinity, but not to
an extent suggesting that any appreciable quantity of the drug had reached the
epidermis. Nothing like neoplastic change was seen in any of these lesions.
DISCUSSION
The incidence, and time of appearance, of benign and malignant tumours in
mice which received an initiating application of DMBA, followed by the various
tumour-promoting treatments, should be compared with that in mice given the
DMBA without subsequent treatment, known from previous work in this labora-
tory using the same strain of mice (Roe, 1956a, and unpublished observations).
For instance 60 mice given one application to the back of 0.3 ml. 0 15 per cent
DMBAin acetone developed no tumours on the treated areas for 40weeks, though
papillomas began to appear elsewhere (mostly on the head) from the 30th week
onwards. No malignant tumours arose on the treated areas; six arose on the head
after an average latent period of 55 weeks.
Onthebasisofcomparisonwiththisseries,theincidenceofbenign and malignant
tumours in Groups 1 and 3 shows that promotion oftumour development in mouse
skin by external application of 20 per cent, and to a less extent of 5 per cent,
phenol has been confirmed. At the higher, but not at the lower, concentration
phenol produced a fewtumours withoutpretreatment with the hydrocarbon. Thus
it is shown to be, like croton oil, an active tumour promoter, but a weak carcinogen,
for mouse skin.
From an attempt to throw light on the role of dermal fibrosis in tumour
promotion, by intradermal injections of phenol and oftwo other sclerosing agents,
the interesting fact emerged that 0-1 per cent aqueous profiavine hemisulphate
injected intradermally after one applicatiou of DMBA is an effective promoting
agent. 0.1 per cent phenol and 1.6per cent ethanolamine oleate, injected similarly,
had slight but definite promoting effects. All these treatments produced nodules
of sclerosis in the dermis, with transient ulceration and hyperplasia of the over-
lying epidermis. When applied without pretreatment with DMBA, only three
tumours appeared among 60 mice-a result which should not be accepted as
significant without further tests.
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As mentioned above, a number of tumours appeared on the heads andnecks of
some of the mice in Groups 5, 6, and 7, which had received an initial treatment of
DMBA on the back followed by intradermal injections of phenol, ethanolamine
oleate, or profiavine hemisulphate. Tumours of the head and neck were not seen
however in Groups 1 and 3, which received 20 per cent and 5 per cent phenol
respectively applied to the skin after the same pretreatment.
Roe (1956a) found that in mice treated with a single application of 0.2 ml.
0 15per cent DMVBA to the back, tumours developed on the head and neck, andon
other sites outside the treated area, from the 30th week onwards. These arose
earlier, and in greater numbers, than tumours on the treated area. It is likely
that the tumours which developed remote from the injection sites in the present
experiment were due to the remote effect of DMBA. It is interesting to note that
in Roe's experiment a course of croton oil treatment to the back after a single
application of DMBA appeared to suppress the development of DMBA tumours
at other sites (Roe, 1956a; and discussion in Salaman and Roe, 1956). It seems
that phenol treatment of the skin had a similar effect in the present experiment,
but that the intradermally injected substances used in Groups 5, 6, and 7 did not.
The question of the role of dermal fibrosis in carcinogenesis, and particularly
in tumour promotion, which was raised by the promoting effect of ulcerative
applications of phenol, has not been conclusively answered. Some relevant
evidence was obtained, and this may be summarized as follows. External applica-
tions of 20 per cent phenol produced much more damage, and resultant hyper-
plasia and scarring, to both epidermis and dermis than 5 per cent. The tumour-
promoting effect of the former was also much greater than that of the latter.
Intradermal injections of sclerosing agents produced, as well as dermal fibrosis,
some ulceration and hyperplasia of the overlying epidermis. Of these proflavine
hemisulphate acted as a fairly powerfull epidermal tumour promoter; but when
applied externally to the skin it was inactive, and produced minimal changes
only in dermis and epidermis. This failure may have been due to lack ofpenetra-
tion. When incorporated in a wax pellet and implanted subcutaneously, proflavine
produced local dermal fibrosis, with late ulceration, but again no epidermal tumour
promotion occurred. Here also lack of penetration by the drug may have been
the cause of its failure to act. However if dermal fibrosis per se can promote
epidermal tumour development, tumours should have arisen in the epidermis over
these pellets (Group 13).
The viewput forward by Orr and his colleagues and which they have supported
by so many ingenious experiments (Orr, 1938, 1948, 1955; Billingham, Orr, and
Woodhouse, 1951; Marchant and Orr, 1953), that epidermal carcinogenesis is
secondary to dermal changes, is not, in the writers' view, either confirmed or
contradicted by the results of the present work.
In every case of tumour promotion there was some irritant action, slight or
severe, of the agent on both the epidermis and the dermis. Until we have means
of affecting each separately it is unlikely that the question of their relative roles
in epidermal carcinogenesis will be finally settled.
SUMMARY
1. The action of phenol at two concentrations applied repeatedly to mouse
skin was tested with or without a single previous application of 9: 10-dimethyl-
1: 2-benzanthracene.
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2. Under these conditions phenol in an ulcerative concentration (20 per cent)
was found to have a strong promoting effect on tumour development, and a weak
carcinogenic action.
3. Phenol in a non-ulcerative concentration (5 per cent) was found to have a
moderate promoting effect on tumour development, but no carcinogenic action.
4. Repeated intradermal injection of three sclerosing agents in just-ulcerating
concentrations, phenol, ethanolamine oleate, and profiavine hemisulphate, were
found to have moderate promoting effects on tumour development. The last was
the most effective.
5. None of these intradermal injections showed significant carcinogenic action.
6. Profiavine hemisulphate applied repeatedly to the surface of the skin, or
implanted subcutaneously as a suspension in paraffin wax, had neither promoting
effect on tumour development, nor any carcinogenic action.
We are indebted to Mr. J. A. Rawlings for care of the animals, and to Messrs.
W. J. Milton and J. Chapman for skilled technical assistance. The expenses of
this research were partly defrayed out of a block grant from the British Empire
Cancer Campaign.
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